Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imexpharm's other long-term assets for the quarter that ended in Jun. 2026 was ₫133,044 Mil.
Imexpharm's quarterly other long-term assets
increased
from Dec. 2025 (₫112,303 Mil) to Mar. 2026 (₫136,912 Mil) but then
stayed the same
from Mar. 2026 (₫136,912 Mil) to Jun. 2026 (₫133,044 Mil).
Imexpharm's annual other long-term assets
declined
from Dec. 2023 (₫148,322 Mil) to Dec. 2024 (₫123,236 Mil) and
declined
from Dec. 2024 (₫123,236 Mil) to Dec. 2025 (₫112,303 Mil).
The historical data trend for Imexpharm's Other Long Term Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.
What does a Other Long Term Assets of ₫133,044 Mil mean?
Imexpharm (STC:IMP) has a Other Long Term Assets of ₫133,044 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Imexpharm and its competitors.
Is Imexpharm's Other Long Term Assets too high?
Imexpharm's current Other Long Term Assets is ₫133,044 Mil. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Other Long Term Assets compare to ZTS?
Imexpharm's Other Long Term Assets of ₫133,044 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Imexpharm and its competitors. Imexpharm's current Other Long Term Assets is ₫133,044 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫47,313.74, compared to a current price of ₫35,100.00 — trading 25.8% below its estimated fair value. The current Other Long Term Assets is ₫133,044 Mil. Imexpharm's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Other Long Term Assets is ₫133,044 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imexpharm (STC:IMP) Overvalued in 2026?
Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued.
The current stock price of ₫35,100.00 is trading 25.8% below its estimated GF Value™ of ₫47,313.74.
GuruFocus considers Imexpharm to be Modestly Undervalued.
Key valuation signals for STC:IMP:
Other Long Term Assets: ₫133,044 Mil
GF Value™: ₫47,313.74 vs. price of ₫35,100.00 (25.8% below fair value)
No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score
Get the complete analysis for STC:IMP
Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:IMP has been successfully added to your 
